E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary Hemochromatosis |
|
E.1.1.1 | Medical condition in easily understood language |
Hereditary Hemochromatosis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057874 |
E.1.2 | Term | Hereditary hemochromatosis |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the response rate in the deferasirox FCT and phlebotomy treatment arms where response is defined
by achieving target SF ≤ 100 μg/L on or before 24 months |
|
E.2.2 | Secondary objectives of the trial |
Key secondary:
Characterize the ocular safety of deferasirox FCT and phlebotomy over 24 months
Other secondary:
- Evaluate the safety and tolerability of deferasirox FCT and phlebotomy over 24 months.
- Assess the change from baseline in visual acuity, intra-ocular pressure, retina or/and optic nerve abnormalities, and lens abnormalities at months 6, 12, 18, and 24 of deferasirox FCT and phlebotomy.
- Assess the safety and tolerability of deferasirox FCT in patients who interrupt and re-initiate treatment due to SF ≤ 100 μg/L and ≥ 300 μg/L
- Assess the first time to response (defined as SF ≤ 100 μg/L) between the deferasirox and phlebotomy treatment groups |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female ≥ 18-years-old
- Documented genotype testing confirming homozygous for the C282Y mutation (C282Y/C282Y)
- Transferrin saturation ≥ 45% (at either screening visit)
- Serum Ferritin ≥ 700 μg/L (at either screening visit) |
|
E.4 | Principal exclusion criteria |
1. Medical conditions that preclude inclusion:
- Iron overload not due to HH
- Condition which might significantly alter the absorption, distribution, metabolism or excretion of oral deferasirox
- Systemic disease which prevents taking study treatment or any contraindication to phlebotomy
- Inflammatory condition or immunological disease which may interfere with the SF interpretation, such as an active infection, collagen vascular disorders, irritable bowel syndrome, lupus, or immune thrombocytopenia
- Significantly impaired gastrointestinal function or disease that may significantly alter the absorption of oral deferasirox, e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption
2. Prior iron chelation therapy, prohibited concomitant medications with deferasirox
syndrome, or small bowel resection.
- Psychiatric or addictive disorder which prevent giving informed consent or undergoing any of the treatment options or unwilling or unable to comply with the protocol
- Uncontrolled or significant cardiac disease or symptomatic cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree AV block without a pacemaker
- Illicit drug use and/or alcohol use, defined as an average alcohol consumption greater than one standard drink a day for women or two standard drinks a day for men within the 12 months prior to enrolment.
- Cirrhosis, including Child-Pugh class A, B, and C, diagnosed by liver biopsy, elastography, radiologic exams, or clinical criteria.
- Active hepatitis B or C (hepatitis B carrier will be allowed)
- History of HIV seropositivity (ELISA or Western blot)
- Malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, except localized basal cell carcinoma of the skin, or any history of hepatocellular carcinoma
3. Abnormal laboratory values
4. Participation in an investigational study:
- Observational registry study is allowable
- Within 30 days prior to enrollment or within 5-half-lives of an investigational product, whichever is longer
- Treatment with a systemic investigational drug within 4 weeks or topical investigational drug within 7 days of starting the study
5. Pregnancy and contraception:
- Pregnant or nursing (lactating) women
- Women of child-bearing potential unless using basic methods of contraception
- Post-menopausal and not of childbearing potential if she has had 12 months of natural (spontaneous) amenorrhea with an expected clinical profile |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients achieving target SF ≤ 100 μg/L for the first time |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary:
Incidence of ocular AEs overall and by severity, type of AE, and relation to study treatment
Other secondary:
- Incidence of AEs, AEs leading to discontinuation from study, laboratory abnormalities, and deaths
- Change from baseline at months 6, 12, 18 and 24 in visual acuity, tonometry, slit lamp, and fundus exams
- Incidence of AEs in patients who interrupt due to reaching target SF ≤ 100 μg/L, then re-initiate therapy at ≥ 300 μg/L
- Time to reach target SF ≤ 100 μg/L in the deferasirox and phlebotomy arms for the first time |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- 24 months
- 24 months
- 6, 12, 18 and 24 months
- 24 months
- 24 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Belgium |
Bulgaria |
France |
Germany |
Romania |
Russian Federation |
Slovakia |
Spain |
Switzerland |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study (EOS) occurs after the last patient has completed the last visit which includes a 30-day safety follow-up. This last patient may have either completed 24 months (104 weeks) of treatment or prematurely discontinued and completed ocular assessments. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |